Silk Road Medical, Inc Provides Revenue Guidance for the Third Quarter Ended September 30, 2023 and Provides Update to Full Year 2023 Revenue Guidance
October 11, 2023 at 01:50 am IST
Share
Silk Road Medical Inc. provided revenue guidance for the quarter ended September 30, 2023 and provides an update to full year 2023 revenue guidance. Preliminary, unaudited third quarter 2023 revenue is expected to be approximately $44.4 million, an increase of 19% as compared to the prior year period.
The company now projects revenue for the full year 2023 to range from $170 million to $174 million, which represents 23% to 26% growth over the Company?s prior year revenue.
Silk Road Medical, Inc. is a medical device company that is focused on reducing the risk of stroke and its impact. The Company has developed an approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. Its product portfolio consists of five single-use components: ENROUTE Transcarotid Neuroprotection System, ENROUTE Transcarotid Stent System, ENHANCE Transcarotid Peripheral Access Kit, ENROUTE 0.014'' Guidewire and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter. It manufactures ENROUTE NPS and ENROUTE NPS PLUS, or its ENROUTE NPS products, at its facilities in Sunnyvale, California and Plymouth, Minnesota. These facilities provide an aggregate of over 35,000 square feet of space for its production and distribution operations.
SILK ROAD MEDICAL, INC 
